The Women's Tennis Association (WTA) has updated its eligibility policy to require all players to undergo a one-time genetic test for the SRY gene, a key marker in determining biological sex, before competing on the women's tour. The test, which can be performed via cheek swab or blood test, takes effect Tuesday, with active player screening set to begin in 2026 under confidentiality and data-privacy protections. The move marks a significant departure from the WTA's previous policy, which allowed transgender women to compete after two years of lowered testosterone levels, and brings the organisation in line with World Athletics, World Boxing, and the International Olympic Committee, all of which have adopted similar genetic screening requirements in recent years.